SHARE PRICE > View All Stock Detailed Share Information Latest News Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS) Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition > View All News All News Upcoming Events More events are coming soon. > View All Events All Events Latest Presentation November 3, 2023 Corporate Presentation - November 2023 August 24, 2023 H1 2023 Results Presentation May 26, 2023 RBC Healthcare Conference Presentation > View All Presentations All Presentations Latest Financial Documents October 26, 2023 Q3 2023 Financial Statement August 24, 2023 H1 2023 Business Update and Financial Statements April 19, 2023 Molecular Partners statement regarding Passive Foreign Investment Company status > View All Reports All Annual Report Seth Lewis, SVP Investor Relations and Strategy Contact Seth STAY INFORMED Subscribe to email alerts of your choosing SUBSCRIBE Institutional investors: REQUEST 1-1 / CALL powered by schedulR
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
